Vasoactive Compounds in Diabetic Therapy

Vasoactive compounds are increasingly recognized for their role in the therapeutic management of diabetes. These compounds, including nitric oxide (NO), angiotensin II, and endothelin, play critical roles in vascular regulation and blood flow. In diabetes, altered levels of vasoactive substances can contribute to endothelial dysfunction and increased cardiovascular risk. Therapeutic agents that modulate these pathways, such as angiotensin-converting enzyme (ACE) inhibitors and NO donors, have shown promise in improving vascular health and mitigating complications associated with diabetes. Understanding the interplay of vasoactive compounds in diabetic therapy is essential for developing comprehensive treatment strategies focused on cardiovascular health and metabolic control.